| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20057253 | HPV | ENSG00000175054.16 | protein_coding | ATR | No | Yes | 545 | Q13535 |
| TVIS20043380 | HPV | ENSG00000175054.16 | protein_coding | ATR | No | Yes | 545 | Q13535 |
| TVIS20044400 | HPV | ENSG00000175054.16 | protein_coding | ATR | No | Yes | 545 | Q13535 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ATR |
|---|---|
| DrugBank ID | DB14917 |
| Drug Name | Ceralasertib |
| Target ID | BE0010060 |
| UniProt ID | Q13535 |
| Regulation Type | inhibitor |
| PubMed IDs | 32878963 |
| Citations | McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM: DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2. |
| Groups | Investigational |
| Direct Classification | |
| SMILES | C[C@@H]1COCCN1C1=NC(=NC(=C1)C1(CC1)[S@](C)(=N)=O)C1=CN=CC2=C1C=CN2 |
| Pathways | |
| PharmGKB | |
| ChEMBL |
